Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies-Reference-Cited by-同舟云学术

Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies

Published:2022-06-01 Issue:23 Volume:7 Page:19243-19260
ISSN:2470-1343
Container-title:ACS Omega
language:en
Short-container-title:ACS Omega

Author:

Hassan Mubashir¹²^ORCID,Yasir Muhammad¹,Shahzadi Saba³,Kloczkowski Andrzej²⁴

Affiliation:

1. Institute of Molecular Biology and Biotechnology, The University of Lahore, Defense Road Campus, Lahore 54590, Pakistan

2. The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Columbus, Ohio 43205, United States

3. Institute of Molecular Sciences and Bioinformatics (IMSB), Nisbet Road, Lahore 52254, Pakistan

4. Department of Pediatrics, The Ohio State University, Columbus, Ohio 43205, United States

Funder

Division of Biological Infrastructure

Ohio State University

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsomega.2c00518

Reference147 articles.

1. The exploration of novel Alzheimer’s therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches

2. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond

3. A Review of Current In Silico Methods for Repositioning Drugs and Chemical Compounds

4. A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions

5. Challenges and Opportunities for Childhood Cancer Drug Development

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicity and therapeutic property of dioxopiperidin derivative SKT40 demonstrated in-vivo zebrafish model due to inflammatory bowel disease;Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology;2024-10

2. Identification of Potential Tryptase Inhibitors from FDA-Approved Drugs Using Machine Learning, Molecular Docking, and Experimental Validation;ACS Omega;2024-09-04

3. Drug Repositioning via Graph Neural Networks: Identifying Novel JAK2 Inhibitors from FDA-Approved Drugs through Molecular Docking and Biological Validation;Molecules;2024-03-19

4. Bioinformatics Analysis Provides Insight into the Identification of miRNAs as Transcriptional Regulators in Respiratory Syncytial Virus Infection;Lecture Notes in Computer Science;2024

5. Machine Learning-Based Drug Repositioning of Novel Janus Kinase 2 Inhibitors Utilizing Molecular Docking and Molecular Dynamic Simulation;Journal of Chemical Information and Modeling;2023-10-31